Obesity is strongly linked to type 2 diabetes, primarily through insulin resistance. Insulin resistance is a key factor in the development of type 2 diabetes and is associated with various metabolic disorders, including hypertension, hyperlipidemia, atherosclerosis, and polycystic ovary syndrome. The mechanisms by which obesity causes systemic insulin resistance are not fully understood, but recent research has focused on the adipo-insulin axis. Insulin resistance and hyperinsulinemia may also contribute to obesity, creating a complex relationship. Insulin plays a critical role in adipocyte function, regulating glucose transport, triglyceride synthesis, and lipolysis. Insulin signaling involves the activation of the insulin receptor tyrosine kinase, leading to the phosphorylation of insulin receptor substrates (IRSs) and subsequent activation of downstream pathways, including PI3K and Akt. However, the exact pathways involved in insulin action remain unclear, with ongoing debates about the role of Akt and PKC in glucose transport. Obesity leads to impaired insulin signaling in adipocytes, skeletal muscle, and the liver, resulting in reduced glucose uptake and metabolism. This is partly due to the downregulation of the glucose transporter GLUT4 and the increased activity of protein tyrosine phosphatases (PTPs), which terminate insulin signaling. In obese individuals, IRS-1 expression is reduced, while IRS-2 becomes the main docking protein for PI3K. Adipose tissue is not only an energy storage depot but also an endocrine organ that secretes hormones, cytokines, and other factors that influence systemic metabolism. Adipocytes secrete TNF-α, which can impair insulin signaling and contribute to insulin resistance. Leptin, another adipocyte-derived hormone, plays a key role in regulating energy balance and glucose homeostasis. However, leptin resistance can limit its effectiveness in preventing obesity. Lipotoxicity, caused by excessive fat storage, leads to increased fatty acid (FFA) flux and insulin resistance. Conversely, lipodystrophy, characterized by the absence of adipose tissue, also results in severe insulin resistance. These conditions highlight the complex role of adipose tissue in insulin sensitivity. Thiazoladinediones (TZDs) improve insulin sensitivity by activating PPARγ, a transcription factor involved in adipogenesis and glucose metabolism. TZDs may act directly in adipose tissue to reduce FFA release or indirectly through effects on other tissues. However, the exact mechanisms of TZD action remain unclear. The relationship between obesity, insulin resistance, and type 2 diabetes is complex, with multiple factors contributing to the development of these conditions. Understanding the molecular and cellular mechanisms underlying insulin resistance is crucial for developing new therapeutic strategies. Advances in research have expanded our understanding of adipocyte function and its role in metabolic regulation, highlighting the importance of adipose tissue in maintaining glucose homeostasis.Obesity is strongly linked to type 2 diabetes, primarily through insulin resistance. Insulin resistance is a key factor in the development of type 2 diabetes and is associated with various metabolic disorders, including hypertension, hyperlipidemia, atherosclerosis, and polycystic ovary syndrome. The mechanisms by which obesity causes systemic insulin resistance are not fully understood, but recent research has focused on the adipo-insulin axis. Insulin resistance and hyperinsulinemia may also contribute to obesity, creating a complex relationship. Insulin plays a critical role in adipocyte function, regulating glucose transport, triglyceride synthesis, and lipolysis. Insulin signaling involves the activation of the insulin receptor tyrosine kinase, leading to the phosphorylation of insulin receptor substrates (IRSs) and subsequent activation of downstream pathways, including PI3K and Akt. However, the exact pathways involved in insulin action remain unclear, with ongoing debates about the role of Akt and PKC in glucose transport. Obesity leads to impaired insulin signaling in adipocytes, skeletal muscle, and the liver, resulting in reduced glucose uptake and metabolism. This is partly due to the downregulation of the glucose transporter GLUT4 and the increased activity of protein tyrosine phosphatases (PTPs), which terminate insulin signaling. In obese individuals, IRS-1 expression is reduced, while IRS-2 becomes the main docking protein for PI3K. Adipose tissue is not only an energy storage depot but also an endocrine organ that secretes hormones, cytokines, and other factors that influence systemic metabolism. Adipocytes secrete TNF-α, which can impair insulin signaling and contribute to insulin resistance. Leptin, another adipocyte-derived hormone, plays a key role in regulating energy balance and glucose homeostasis. However, leptin resistance can limit its effectiveness in preventing obesity. Lipotoxicity, caused by excessive fat storage, leads to increased fatty acid (FFA) flux and insulin resistance. Conversely, lipodystrophy, characterized by the absence of adipose tissue, also results in severe insulin resistance. These conditions highlight the complex role of adipose tissue in insulin sensitivity. Thiazoladinediones (TZDs) improve insulin sensitivity by activating PPARγ, a transcription factor involved in adipogenesis and glucose metabolism. TZDs may act directly in adipose tissue to reduce FFA release or indirectly through effects on other tissues. However, the exact mechanisms of TZD action remain unclear. The relationship between obesity, insulin resistance, and type 2 diabetes is complex, with multiple factors contributing to the development of these conditions. Understanding the molecular and cellular mechanisms underlying insulin resistance is crucial for developing new therapeutic strategies. Advances in research have expanded our understanding of adipocyte function and its role in metabolic regulation, highlighting the importance of adipose tissue in maintaining glucose homeostasis.